Supernus Pharmaceuticals/$SUPN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Supernus Pharmaceuticals
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
Ticker
$SUPN
Sector
Primary listing
Employees
778
Headquarters
Website
SUPN Metrics
BasicAdvanced
$2.7bn
-
-$0.51
0.57
-
Price and volume
Market cap
$2.7bn
Beta
0.57
52-week high
$59.68
52-week low
$30.83
Average daily volume
694k
Financial strength
Current ratio
1.956
Quick ratio
1.515
Long term debt to equity
2.811
Total debt to equity
3.799
Profitability
EBITDA (TTM)
122.628
Gross margin (TTM)
74.13%
Net profit margin (TTM)
-3.74%
Operating margin (TTM)
3.26%
Effective tax rate (TTM)
40.96%
Revenue per employee (TTM)
$1,000,000
Management effectiveness
Return on assets (TTM)
1.11%
Return on equity (TTM)
-2.75%
Valuation
Price to revenue (TTM)
3.431
Price to book
2.53
Price to tangible book (TTM)
6.69
Price to free cash flow (TTM)
32.411
Free cash flow yield (TTM)
3.09%
Free cash flow per share (TTM)
1.446
Growth
Revenue change (TTM)
16.29%
Earnings per share change (TTM)
-146.07%
3-year revenue growth (CAGR)
5.13%
10-year revenue growth (CAGR)
16.91%
3-year earnings per share growth (CAGR)
-17.18%
10-year earnings per share growth (CAGR)
4.34%
What the Analysts think about SUPN
Analyst ratings (Buy, Hold, Sell) for Supernus Pharmaceuticals stock.
SUPN Financial Performance
Revenues and expenses
SUPN Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs